Keywords: Merck KGaA, Bio-Techne acquisition, life sciences M&A, TECH stock deal, Sigma-Aldrich comparison, biotech tools merger

Key Highlights

  • Bio-Techne Corporation (NASDAQ:TECH) shareholders approved Merck KGaA's Acquisition agreement at a special meeting on September 23, 2026, clearing the final hurdle to close the deal.
  • The transaction, first announced in June 2026, values Bio-Techne at approximately USD 11.3 billion and is Merck KGaA's largest acquisition since its 2015 purchase of Sigma-Aldrich.
  • Shareholders separately rejected a non-binding advisory proposal on merger-related executive compensation, even as they approved the underlying Merger itself.
  • The deal strengthens Merck KGaA's position in life sciences tools, adding Bio-Techne's protein analysis, genomics, and diagnostics businesses to its portfolio.

Shareholder Vote Clears Final Hurdle

At a special meeting on September 23, 2026, Bio-Techne shareholders voted to approve the merger agreement under which Merck KGaA, Darmstadt, Germany will acquire the company. The approval was the last major condition standing between the deal's June 2026 signing and its completion, following earlier regulatory clearances. In the same meeting, shareholders voted down a separate, non-binding advisory proposal on compensation tied to the merger for Bio-Techne executives, a procedural outcome that does not affect the deal's ability to close.

Deal Size and Strategic Rationale

The acquisition values Bio-Techne at approximately USD 11.3 billion, making it Merck KGaA's largest transaction since its roughly USD 17 billion purchase of Sigma-Aldrich in 2015. Bio-Techne supplies proteins, antibodies, and instruments used in biomedical research, diagnostics, and genomics, complementing Merck KGaA's existing life sciences division. The deal reflects continued consolidation among life sciences tools suppliers as larger players seek scale in genomics and protein analysis markets.

What Comes Next

With Shareholder approval secured, Merck KGaA and Bio-Techne are positioned to move toward final closing of the transaction. Bio-Techne is expected to operate as part of Merck KGaA's life sciences Business following completion, with the German group having flagged the acquisition as central to expanding its footprint in high growth diagnostics and genomics tooling markets.

Where Things Stand

The September 23 shareholder vote removes the last significant hurdle to Merck KGaA's USD 11.3 billion purchase of Bio-Techne, positioning the deal to close and mark the German conglomerate's biggest life sciences bet in over a decade. The combination underscores continued consolidation pressure among suppliers of research and diagnostic tools worldwide.